Obstructive sleep apnea (OSA) is a highly prevalent condition that has been associated with cardiovascular morbidity and mortality, impaired glucose metabolism and daytime functional impairment. Compared with nonrapid eye movement sleep, rapid eye movement (REM) sleep is associated with higher sympathetic activity and cardiovascular instability in healthy individuals and more so in patients with OSA.
INTRODUCTION
In 1953, University of Chicago investigators Nathaniel Kleitman and Eugene Aserinsky [1] discovered rapid eye movement (REM) sleep. In healthy adult humans, REM sleep accounts for approximately 20% of total sleep time and it is mostly concentrated in the second half of the sleep period. To date, the majority of research on REM sleep has focused on memory, affect and cognition. However, there are important autonomic nervous system and cardiorespiratory changes that occur in REM sleep compared with nonrapid eye movement (NREM) sleep that, taken together, support the view that obstructive sleep apnea (OSA) during REM sleep may have worse cardiometabolic consequences than during NREM sleep.
OSA is a highly prevalent disorder that is associated with significant morbidity and mortality [2, 3] . It is characterized by intermittent partial (hypopnea) or complete (apnea) upper airway collapse that leads to recurring episodes of hypoxemia and hypercapnia, sleep fragmentation and increased sympathetic activity. OSA during REM sleep is a condition in which hypopneas and apneas occur primarily during REM sleep. The clinical significance of REM OSA remains controversial [4, 5] . Our knowledge of the prevalence and clinical implications of REM OSA has increased in recent years. What follows is an overview of the most current research findings regarding REM OSA.
PREVALENCE OF RAPID EYE MOVEMENT-RELATED OBSTRUCTIVE SLEEP APNEA
The reported prevalence of REM OSA has been based mostly on clinical studies with small cohorts. Because of the inconsistent definitions used in the literature, the reported prevalence has ranged between 10 and 36% [21] [22] [23] [24] . REM OSA has been defined in a variety of ways including overall apneahypopnea index (AHI) at least 5 with AHI REM /AHI NREM ratio at least 2; overall AHI at least 5 with AHI REM / AHI NREM ratio at least 2 and with AHI NREM less than 15; overall AHI at least 5, AHI REM /AHI NREM ratio at least 2 and with AHI NREM less than 8. In a cross-sectional study evaluating 1019 consecutive adults who were referred for their first in-laboratory full night polysomnography (PSG) for suspected OSA, the prevalence of REM OSA ranged from 13.5 to 36.7% depending on the used definition, which is similar to the prevalence rates reported in previous clinical studies [25] . In this large cross-sectional study, REM OSA was more prevalent in women, younger individuals and African Americans [25] .
The prevalence of OSA during REM sleep is also similarly high in community-based cohorts. In the Wisconsin Sleep Cohort, 18% of the sleep studies with no evidence of OSA (i.e. AHI <5) demonstrated moderate or severe OSA during REM sleep (i.e. REM AHI !15). Also, 70% of the sleep studies with an overall AHI less than 15 (i.e. no OSA and mild OSA) had an REM AHI at least 15 [26 & ]. Likewise, in the Sleep Heart Health Study, 25% of individuals with an NREM AHI less than 8 had an REM AHI at least 13 [27] . Furthermore, in a recent study by Appleton et al. [28 && ] involving the Men Androgens Inflammation Lifestyle Environment and Stress (MAILES) Study, 15% of the community-dwelling men without 'clinically significant' OSA (i.e. AHI <10) had an REM AHI at least 20. Taken together, these findings suggest that REM predominant OSA is prevalent in clinical populations as well as in the community.
RAPID EYE MOVEMENT OBSTRUCTIVE SLEEP APNEA AND HYPERTENSION
Longitudinal studies have had contradicting evidence regarding the association of OSA with incident hypertension. An increased risk of incident hypertension from OSA was observed in the Wisconsin Sleep Cohort Study [29] , whereas the Sleep Heart Health Study [30] and the Vitoria Sleep Cohort [31] found the relationship was not significant after adjusting for covariates such as BMI and age.
However, a recent report from an extended follow-up of the Wisconsin Sleep Cohort demonstrated that REM OSA is independently associated with prevalent hypertension in cross-sectional analysis and with incident hypertension in longitudinal analysis. These associations became more robust in a subset of patients in whom ambulatory blood pressure monitoring (ABPM) was used to define hypertension. Importantly, AHI during NREM sleep
KEY POINTS
REM predominant OSA is a prevalent disorder that is independently associated with adverse cardiometabolic outcomes and impairment of human spatial navigational memory.
Prolonged CPAP usage that includes the early morning hours before awakening in patients with REM predominant OSA should be emphasized by clinicians.
Further research is needed to address the treatment of patients with REM OSA who have an overall normal AHI.
had no significant association with prevalent or incident hypertension after adjusting for REM AHI. Moreover, to further validate the relationship between REM OSA and hypertension, the investigators performed additional analysis in a subset of participants who had no disease in NREM sleep (i.e. NREM AHI < 5). In this subset, increasing quartiles of REM AHI were strongly associated with hypertension, suggesting a dose-relationship between REM AHI and hypertension [26 & ]. Specifically, the risk of hypertension increased significantly when REM AHI was greater than or equal to 15. In individuals with NREM AHI of less than 5, a two-fold increase in REM AHI was associated with 24% higher odds of hypertension.
Appleton et al. [28 && ] most recently examined the temporal associations of previously unrecognized or undiagnosed OSA, including REM OSA, with hypertension. This was examined in 739 middle-aged and elderly community-dwelling men enrolled in the MAILES Study, a populationbased longitudinal cohort from Adelaide, Australia. REM OSA (REM AHI !30/h) demonstrated an independent association with prevalent and recentonset hypertension [odds ratio (OR) 2.40, 95% confidence interval (CI) 1.42-4.06, and OR 2.24, 95% CI 1.04-4.81, respectively]. In contrast, and similar to the Wisconsin Sleep Cohort analysis, NREM AHI was not associated with hypertension after adjusting for REM AHI. In men with AHI less than 10, REM AHI at least 20/h was significantly associated with prevalent hypertension (OR 2.67, 95% CI 1. 33-5.38 ).
In healthy individuals, BP normally varies during different physiologic states and declines by more than 10-20% at nighttime during sleep compared with daytime waking BP. Nondipping BP has important clinical implications because it is a marker for future development of hypertension in those who are normotensive. Moreover, nondipping BP has been associated with worse cardiovascular prognosis and increased target organ damage, including left ventricular hypertrophy, myocardial infarction, angina, ischemic stroke and cardiovascular death [32] . Another longitudinal analysis of the Wisconsin Sleep Cohort assessed 269 adults who completed two or more 24-h ABPM studies over an average of 6.6 years of follow-up. The goal of the study was to evaluate the association of REM-related OSA and incident nondipping of BP in a sample selected regardless of the presence of OSA symptoms or comorbidities [33 & ]. The study demonstrated that OSA in REM sleep, independent of NREM OSA, was associated with the development of nocturnal systolic and diastolic nondipping of BP over an average follow-up period of 6.6 years among participants who initially were normal nocturnal BP dippers.
The association also showed a dose-response gradient: individuals with a baseline REM AHI at least 15 had an approximately three-fold greater relative risk of developing systolic nondipping and a fourfold greater relative risk of developing diastolic nondipping compared with those with REM AHI less than 1.
Therefore, there is a convergence of data from two population-based studies from distinct geographical regions demonstrating a significant and clinically relevant association between OSA during REM sleep and prevalent hypertension, incident hypertension as well as incident nocturnal nondipping of BP.
RAPID EYE MOVEMENT OBSTRUCTIVE SLEEP APNEA AND GLUCOSE METABOLISM
From a metabolic standpoint, elevated REM AHI has been independently associated with insulin resistance. In the community-based Sleep Heart Health Study, increased REM AHI was associated with increased insulin resistance but not with impaired fasting glucose or glucose intolerance after adjustment for multiple potential confounders, including age, sex, race, adiposity, self-reported sleep duration and NREM AHI. In contrast, increased NREM AHI was associated with impaired fasting glucose and glucose intolerance after adjusting for adiposity. This finding suggests that REM-related OSA may impact glucose metabolism even in the absence of NREM OSA [34 && ]. Two studies that performed continuous interstitial glucose monitoring simultaneously with PSG directly support the hypothesis that REM-related OSA may have adverse metabolic consequences [35, 36] . One of these studies included 13 obese patients with type 2 diabetes and severe OSA and compared them with 13 obese patients with type 2 diabetes without OSA with similar demographic characteristics. The mean glucose level was 38% higher during REM sleep in those with OSA [35] . The second study included 11 nondiabetic individuals. They found that in the absence of OSA, REM sleep leads to a larger decline in interstitial glucose concentration than NREM sleep. OSA during REM sleep, however, abolished the expected decline in interstitial glucose concentration. In contrast, OSA during NREM sleep had no impact on interstitial glucose concentrations [36] .
Increasing severity of disordered breathing during REM sleep is also associated with worse glycemic control in type 2 diabetes. In a prospective study of 115 individuals with type 2 diabetes enrolled from the community (65 women, age 55.2 AE 9.8 years; BMI 34.5 AE 7.5 kg/m 2 ), REM AHI was independently associated with increasing levels of hemoglobin A1c (HbA1c) (P ¼ 0.008). In contrast, NREM AHI was not associated with HbA1c (P ¼ 0.762). The mean adjusted HbA1c increased from 6.3% in individuals in the lowest quartile of REM AHI to 7.3% in individuals in the highest quartile of REM AHI, a clinically significant effect size [37 & ]. To obtain definite evidence regarding the clinical efficacy of continuous positive airway pressure (CPAP) treatment to improve glucose control in type 2 diabetes, we recently completed a proof-ofconcept study that was designed to test the hypothesis that 1 week of full night CPAP treatment of OSA in the laboratory, as compared with sham-CPAP (placebo), results in improvement in glycemic control as assessed by mean plasma glucose levels from 24-h blood sampling [38 & ]. In this study, we employed a rigorous methodology of 24-h blood sampling, adherence to standardized meals during 24-h blood sampling and ensuring CPAP adherence in order to address important limitations faced by several prior studies such as solely relying on fasting measures of glucose and insulin or HbA1c or being limited by low CPAP adherence. In this study, adherence to CPAP was monitored nightly in the sleep laboratory. The 24-h mean plasma glucose decreased significantly more after 1 week of active vs. sham CPAP treatment (-13.7 AE 3.6 mg/dl vs. -2.9 AE 1.4 mg/dl; P ¼ 0.013). This decrease in mean plasma glucose was associated with a trend for lower 24-h mean insulin levels (-25.8 AE 16.5 pmol/l vs. 28.4 AE 21.6 pmol/l; P ¼ 0.071). Improvement in glucose levels was most prominent during the overnight period, resulting in lower morning fasting glucose levels. The degree of improvement seen with 1 week of full adherence to CPAP was similar to that achieved by oral pharmacologic agents and equivalent to a drop of 0.4-0.5% in the HbA1c levels. This improvement in glycemic control without an increase in serum insulin levels suggests that elimination of OSA decreases insulin resistance. Our study demonstrates that if CPAP is used during the entire 8-h sleep period, and therefore covering all REM sleep, it can lead to significant glycemic improvement in patients with OSA and type 2 dia-
Collectively, these studies support the notion that OSA during REM sleep is adversely associated with glucose metabolism. However, despite these important associations between REM OSA and glusose metabolism, there is a need for additional research.
Refer to 
OBSTRUCTIVE SLEEP APNEA DURING RAPID EYE MOVEMENT SLEEP AND NEUROCOGNITIVE FUNCTION
Several studies have shown that OSA during REM sleep is not associated with excessive daytime sleepiness (based on a subjective sleepiness questionnaire or multiple sleep latency test) or quality of life [27, [39] [40] [41] [42] . However, sleepiness questionnaires and the multiple sleep latency test are not designed to detect impairments of neurocognitive function [5] . Studies in rodents have shown that REM sleep suppression leads to impairment of spatial memory [43, 44] . These findings were confirmed in humans in a recent study where 18 individuals with severe OSA on chronic CPAP therapy underwent 1 night of CPAP withdrawal only during REM sleep (i.e. creating a model of REM-specific OSA by lowering the CPAP pressure to nontherapeutic settings during REM sleep) [45 & ]. This condition of CPAP withdrawal during REM sleep led to reemergence of severe OSA during REM sleep (REM AHI of 46.1 AE 3.5 events/h) accompanied by REM sleep fragmentation without any effect on total sleep time, sleep efficiency and NREM slow wave sleep. The study showed that a normal overnight sleep while on CPAP consolidated spatial navigational memories. These benefits were completely lost when REM sleep was disrupted by 1 night of CPAP withdrawal exclusively during REM sleep. This finding suggests that fragmentation of REM sleep as occurs in REM OSA has deleterious effects on spatial navigational memory. However, additional studies are needed to better delineate the deleterious effect on untreated REM OSA on neurocognitive function.
CLINICAL SIGNIFICANCE OF RAPID EYE MOVEMENT OBSTRUCTIVE SLEEP APNEA IN THE CONTEXT OF CONTINUOUS POSITIVE AIRWAY PRESSURE THERAPY
In clinical practice, 4 h of nightly CPAP use for 70% of the nights is considered adequate adherence to therapy [46] . This translates into an average CPAP use of 2.8 h every night. Indeed, it is plausible that reduced CPAP adherence and the predominantly untreated OSA during REM sleep (which prevails during the latter hours of normal nocturnal sleep) may explain the negative or modest effects of CPAP therapy on BP and glycemic control in randomized clinical trials. In a recent randomized controlled trial examining the effect of CPAP on incidence of hypertension or cardiovascular events in nonsleepy OSA patients, the investigators found that CPAP did not improve outcomes based on intention-to-treat analysis [47] . However, in posthoc analyses, the investigators reported a significant reduction in incident hypertension or cardiovascular events in those that were adherent to CPAP therapy (median use of 6 h/night). In another randomized controlled trial of patients with OSA and resistant hypertension, there was a significant positive correlation between hours of CPAP use and the decrease in 24-h mean BP [48] . In a prospective study of 115 participants with type 2 diabetes, we reported that 3 and 4 h of CPAP use after lights were turned off would leave 75 and 60% of obstructive events during REM sleep untreated, respectively [37 & ]. Therefore, on the basis of our data, the failure to treat REM OSA because of insufficient CPAP use may have clinical relevance in the context of mitigating its adverse cardiovascular and metabolic consequences [26 & 
,33
& ,37 & ]. In this context, it would be of clinical interest to explore the effectiveness of oral appliances in treating OSA during REM sleep, particularly that adherence to oral appliances tends to be better than with CPAP. REM OSA, defined by REM AHI thresholds that are strongly associated with hypertension, is quite prevalent in the community at large and in individuals who would not be considered as having 'clinically significant' OSA using current clinical definitions. Further research is needed to establish whether treatment can decrease the cardiovascular and metabolic risk associated with REM OSA.
More attention should be given to increasing adherence to CPAP treatment in patients with OSA to cover the early morning hours before awakening in order to more effectively treat OSA during REM sleep. Those findings also emphasize the need to personalize OSA therapy. Not all patients with OSA fit into one phenotype. Further research and larger studies focusing on REM OSA are needed to redefine treatment strategies for REM OSA.
CONCLUSION
REM OSA is quite prevalent and is associated with adverse cardiovascular and metabolic outcomes. Current CPAP adherence guidelines may leave the majority of REM OSA untreated. Clinicians should emphasize the need for more prolonged CPAP usage that includes the early morning hours before awakening in patients with REM predominant OSA. Further research is needed to address the treatment of patients with REM OSA who have an overall normal AHI.
